CompBrief BY VELARION

Companies Spero Therapeutics, Inc.

Spero Therapeutics CEO salary & total pay, FY2025: $2.1M

Spero Therapeutics (SPRO) CEO salary, fiscal 2025: Esther Rajavelu was paid a salary of $577,179 and $2,061,496 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Spero Therapeutics, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Esther Rajavelu's complete compensation dossier

A PDF and a CSV sent to your email: Esther Rajavelu's pay in every fiscal year Spero Therapeutics, Inc. reported it, line by line, with Esther Rajavelu's equity grants and Spero Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$2,061,496CEO Esther Rajavelu · source
Say-on-pay support96.53%Latest vote · source

CEO pay, last three years

  • $2,385,905FY2023
  • $856,479FY2024
  • $2,061,496FY2025

CEO total pay was $2,061,496 in fiscal 2025, up from $856,479 in fiscal 2024.

FY2025: salary $577,179 · bonus $687,479 · stock awards $413,705 · option awards $0

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Spero Therapeutics, Inc. in fiscal 2025?
As disclosed, Esther Rajavelu (President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer(5)) was the highest-paid executive at Spero Therapeutics, Inc. in fiscal 2025, with total compensation of $2,061,496.
How did shareholders vote on Spero Therapeutics, Inc.'s executive compensation?
As disclosed, 96.53% of shareholders supported Spero Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Spero Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Spero Therapeutics, Inc. reported total board compensation of $1,226,150 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Esther Rajavelu$577,179$687,479$413,705$0$372,000$0$11,134$2,061,496
President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer(5)
Satyavrat Shukla244,153452,813603,3800307,9120416,9192,025,178
Former President and Chief Executive Officer(6)
Tim Keutzer484,566498,818213,7100232,592011,1341,440,820
Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Esther Rajavelu$2,061,496$856,479—↑ +1,205,017
Satyavrat Shukla2,025,1781,953,2372,024,647↑ +71,941
Tim Keutzer1,440,8201,033,450—↑ +407,370

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantMeridian Compensation Partners, LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingfalse
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Esther RajaveluRSU—150,000—$349,500
Esther RajaveluRSU—89,899—209,465
Esther RajaveluRSU—366,139—853,104
Esther RajaveluRSU—185,000—431,050
Tim KeutzerOption50,9742,21611.18—
Tim KeutzerRSU—9,503—22,142
Tim KeutzerRSU—132,978—309,839
Tim KeutzerRSU—179,798—418,929
Tim KeutzerRSU—266,139—620,104
Tim KeutzerOption55,943—5.9—
Tim KeutzerOption25,016—11.63—
Tim KeutzerOption25,000—6.26—
Tim KeutzerOption55,000—9.34—
Tim KeutzerOption57,432—19.18—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
John C. Pottage Jr., M.DNot independent · Development (Chair)$50,000$57,800——$225,000$332,800
Frank E. ThomasIndependent · Board Chair130,00057,800——0187,800
Patrick Vink, M.DIndependent · Nominating and Corporate Governance (Chair) · Compensation83,75057,800——0141,550
Milind Deshpande, Ph.DIndependent · Audit · Nominating and Corporate Governance · Development62,50057,800——0120,300
Cynthia SmithIndependent · Compensation (Chair)60,00057,800——0117,800
Scott JacksonIndependent · Audit · Nominating and Corporate Governance57,50057,800——0115,300
Kathleen TregoningIndependent · Compensation50,00057,800——0107,800
Ankit Mahadevia, M.DNot independent · Development45,00057,800——0102,800
Esther RajaveluEmployee director—————0

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$20,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 20,000 / 15,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$538,750
Equity awards (grant-date value)$462,400
All other compensation$225,000
Total cost of the board$1,226,150

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Spero Therapeutics as a peer

Companies that benchmark against SPRO

1 company names SPRO as a compensation peer

Each company listed discloses SPRO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SPRO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Spero Therapeutics, Inc.2025Esther Rajavelu$577,179$413,705$0$372,000$2,061,496

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-2327,890,2541,002,982107,17496.53%Passed
20252025-06-1225,178,672638,744354,78497.53%Passed
20242024-05-2923,890,281442,014404,37198.18%Passed
20232023-10-0520,123,6471,145,027259,28594.62%Passed
20222022-09-15—————
20212021-08-17—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20262026-06-2396.53%a
20252025-06-1297.53%b
20242024-05-2998.18%c

a. Approved under the standard stated in the filing — “Proposal 2: Ratify Appointment of Independent Registered Public Accounting Firm The affirmative vote of the holders of a majority in voting power of the votes cast by the holders of the shares of our common stock present or represented at the meeting and voting affirmatively or negatively for this proposal is required to ratify the appointment of our independent registered public accounting firm. || Abstentions: Abstentions will have no effect on the results of this vote.”.

b. Approved under the standard stated in the filing — “Proposal 3: Advisory Vote on Compensation of the Company's Named Executive Officers The affirmative vote of a majority in voting power of the votes cast by the holders of the shares of our common stock present or represented at the meeting and voting affirmatively or negatively for this proposal is required to approve the advisory vote on the compensation of our named executive officers, as described in this proxy statement. || Abstentions: Abstentions will have no effect on the results of this vote.”.

c. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Esther RajaveluSee Remarks2026-05-04D25,240$3$63,352CommonForm 4 ↗
Frank E. ThomasDirector2026-06-23A20,00000Derivative, Class A CommonForm 4 ↗
Frank E. ThomasDirector2026-06-23A10,00000CommonForm 4 ↗
Kathleen TregoningDirector2026-06-23A10,00000CommonForm 4 ↗
Cynthia SmithDirector2026-06-23A20,00000Derivative, Class A CommonForm 4 ↗
Cynthia SmithDirector2026-06-23A10,00000CommonForm 4 ↗
John C. Pottage JrDirector2026-06-23A20,00000Derivative, Class A CommonForm 4 ↗
John C. Pottage JrDirector2026-06-23A10,00000CommonForm 4 ↗
Scott JacksonDirector2026-06-23A20,00000Derivative, Class A CommonForm 4 ↗
Scott JacksonDirector2026-06-23A10,00000CommonForm 4 ↗
Patrick V.j.j. VinkDirector2026-06-23A20,00000Derivative, Class A CommonForm 4 ↗
Patrick V.j.j. VinkDirector2026-06-23A10,00000CommonForm 4 ↗
Kathleen TregoningDirector2026-06-23A20,00000Derivative, Class A CommonForm 4 ↗
Milind DeshpandeDirector2026-06-23A20,00000Derivative, Class A CommonForm 4 ↗
Milind DeshpandeDirector2026-06-23A10,00000CommonForm 4 ↗
Debra ZackChief Medical Officer2026-08-03A324,67500Derivative, Class A CommonForm 4 ↗
Debra ZackChief Medical Officer2026-08-03A162,31100CommonForm 4 ↗
Esther RajaveluDirector2026-11-09D40,851142,485CommonForm 4 ↗
William HoDirector2026-11-10A100,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (37 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Esther Rajavelu. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · page 23. As printed: 2,061,496. View filing ↗
  • Section 01, Satyavrat Shukla. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 2,025,178. View filing ↗
  • Section 01, Tim Keutzer. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 1,440,820. View filing ↗
  • Section 08, John C. Pottage Jr., M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 332,800. View filing ↗
  • Section 08, Frank E. Thomas. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 187,800. View filing ↗
  • Section 08, Patrick Vink, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 141,550. View filing ↗
  • Section 08, Milind Deshpande, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 120,300. View filing ↗
  • Section 08, Cynthia Smith. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 117,800. View filing ↗
  • Section 08, Scott Jackson. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 115,300. View filing ↗
  • Section 08, Kathleen Tregoning. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 107,800. View filing ↗
  • Section 08, Ankit Mahadevia, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 102,800. View filing ↗
  • Section 08, Esther Rajavelu. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Esther Rajavelu 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank E. Thomas 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank E. Thomas 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kathleen Tregoning 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Cynthia Smith 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Cynthia Smith 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John C. Pottage Jr 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John C. Pottage Jr 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scott Jackson 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scott Jackson 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Patrick V.j.j. Vink 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Patrick V.j.j. Vink 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kathleen Tregoning 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Milind Deshpande 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Milind Deshpande 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Debra Zack 2026-08-03. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Debra Zack 2026-08-03. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Esther Rajavelu 2026-11-09. Form 4, filed 2026-11-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, William Ho 2026-11-10. Form 4, filed 2026-11-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-06-25. Item 5.07 · say-on-pay result. As reported: 96.53% (votes for as printed: 27,890,254). View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 97.53% (votes for as printed: 25,178,672). View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-03. Item 5.07 · say-on-pay result. As reported: 98.18% (votes for as printed: 23,890,281). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 538,750 + equity 462,400 + all other 225,000 = 1,226,150, summed across the director compensation table rows.
  • Spero Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Spero Therapeutics, Inc.'s own proxy. As printed: 2,061,496. View filing ↗
Get the full report — $299